A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

Toshio Shimizu(Wakayama Medical University), Kazuhiko Nakagawa(Kindai University Hospital), Mitchell Keegan(Verastem (United States)), Ajit Chavan(Verastem (United States)), Mahesh V. Padval(Verastem (United States)), Masayuki Takeda(Kindai University), Takeshi Yoshida(Kanazawa University), Joanna Horobin(Verastem (United States)), Kazuya Fukuoka(Kindai University), Lou Vaickus(Verastem (United States))
Cancer Chemotherapy and Pharmacology
March 30, 2016
10.1007/s00280-016-3010-1
Cited by 109

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
|JAMA Oncology|2017|1k